array:5 [
  "content-type" => array:1 [
    0 => "text/html; charset=UTF-8"
  ]
  "cache-control" => array:1 [
    0 => "no-cache, private"
  ]
  "date" => array:1 [
    0 => "Sun, 19 Jan 2025 17:14:17 GMT"
  ]
  "set-cookie" => array:2 [
    0 => "XSRF-TOKEN=eyJpdiI6Im5Bb2YyZ000SlIrWFhmWTdWcFkrVHc9PSIsInZhbHVlIjoia0xocUtOSU1pcTNRakF6TE42a3pMdjRMcVZ5NCtjMmVwMmw4QlR6WlA5dmh3OGYwdytpaXAzc0pldDJSNjI4WGJkMGNOaktEdGhhc2RFdFVXUXhwanJyMk9TVmxFN0hacDhxODFzNUc0MzFiZFYyQmtxTkZVVUhuSk1HR2U4ZlUiLCJtYWMiOiJhZjBiMGM4ODIzODYwOGIxMDY3ZWZkYzI0OGYxOTE5ZmZkMGUyNmUyYzJmMmFjZDkzZDgxZjgzOTYxOTZmNmFkIiwidGFnIjoiIn0%3D; expires=Mon, 19 Jan 2026 17:14:17 GMT; Max-Age=31536000; path=/; secure; samesite=lax"
    1 => "republica_session=eyJpdiI6ImpHTk5mYVZvbWZTczFRSFJMMkp1V2c9PSIsInZhbHVlIjoiZlhjVitWdFJEdG5zYlNpaGFYUm1XN1RXampRWTVYbEl1QiswNkFOZCt3S0FxSy9qZ1N0SElmS2tBQ0k3MldOZFkzWUJoc1pQQlRIenZGTFlkZVVDcnk2SmVPWVE3ZytLdkRFL082ZlNreGlMVmJ3YlZxS25Lc3JXWGo3bmJhUmUiLCJtYWMiOiIzNGMyNGE1MWRmMmIzZGRkZDc2YWM2ZmNlNzE2MjlkOTY3MjZiMjRkMzg5NGJjN2JlNzAxOWU4ODNiNTNlN2E2IiwidGFnIjoiIn0%3D; expires=Mon, 19 Jan 2026 17:14:17 GMT; Max-Age=31536000; path=/; secure; httponly; samesite=lax"
  ]
  "Set-Cookie" => array:2 [
    0 => "XSRF-TOKEN=eyJpdiI6Im5Bb2YyZ000SlIrWFhmWTdWcFkrVHc9PSIsInZhbHVlIjoia0xocUtOSU1pcTNRakF6TE42a3pMdjRMcVZ5NCtjMmVwMmw4QlR6WlA5dmh3OGYwdytpaXAzc0pldDJSNjI4WGJkMGNOaktEdGhhc2RFdFVXUXhwanJyMk9TVmxFN0hacDhxODFzNUc0MzFiZFYyQmtxTkZVVUhuSk1HR2U4ZlUiLCJtYWMiOiJhZjBiMGM4ODIzODYwOGIxMDY3ZWZkYzI0OGYxOTE5ZmZkMGUyNmUyYzJmMmFjZDkzZDgxZjgzOTYxOTZmNmFkIiwidGFnIjoiIn0%3D; expires=Mon, 19-Jan-2026 17:14:17 GMT; path=/; secure"
    1 => "republica_session=eyJpdiI6ImpHTk5mYVZvbWZTczFRSFJMMkp1V2c9PSIsInZhbHVlIjoiZlhjVitWdFJEdG5zYlNpaGFYUm1XN1RXampRWTVYbEl1QiswNkFOZCt3S0FxSy9qZ1N0SElmS2tBQ0k3MldOZFkzWUJoc1pQQlRIenZGTFlkZVVDcnk2SmVPWVE3ZytLdkRFL082ZlNreGlMVmJ3YlZxS25Lc3JXWGo3bmJhUmUiLCJtYWMiOiIzNGMyNGE1MWRmMmIzZGRkZDc2YWM2ZmNlNzE2MjlkOTY3MjZiMjRkMzg5NGJjN2JlNzAxOWU4ODNiNTNlN2E2IiwidGFnIjoiIn0%3D; expires=Mon, 19-Jan-2026 17:14:17 GMT; path=/; secure; httponly"
  ]
]

Enrollment begins for Sanofi and GSK Phase 3 efficacy trial of COVID-19 vaccine candidate in Nepal, led by IVI

Enrollment begins for Sanofi and GSK Phase 3 efficacy trial of COVID-19 vaccine candidate in Nepal, led by IVI

Create an account, or log in